

Journalbeiträge

1. Behnes CL, Hemmerlein B, Strauss A, Radzun HJ, Bremmer F (2012) N-cadherin is differentially expressed in histological subtypes of papillary renal cell carcinoma. *DIAGN PATHOL*, 7: 95.
2. Bolenz C, Auer M, Ströbel P, Heinzlbecker J, Schubert C, Trojan L (2012) The lymphatic system in clinically localized urothelial carcinoma of the bladder: Morphologic characteristics and predictive value. *UROL ONCOL-SEMIN ORI*, x: x.
3. Bremmer F, Thelen P, Pottek T, Behnes CL, Radzun HJ, Schweyer S (2012) Expression and function of the vitamin D receptor in malignant germ cell tumour of the testis. *ANTICANCER RES*, 32(1): 341-9.
4. Bremmer F, Hemmerlein B, Strauss A, Burfeind P, Thelen P, Radzun HJ, Behnes CL (2012) N-cadherin expression in malignant germ cell tumours of the testis. *BMC Clin Pathol*, 12(1): 19.
5. Bremmer F, Kessel FJ, Behnes CL, Trojan L, Heinrich E (2012) Leiomyoma of the tunica albuginea, a case report of a rare tumour of the testis and review of the literature. *DIAGN PATHOL*, 7: 140.
6. Gabriel U, Li L, Bolenz C, Steidler A, Kränzlin B, Saile M, Gretz N, Trojan L, Michel MS (2012) New insights into the influence of cigarette smoking on urothelial carcinogenesis: smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer. *MOL CARCINOGEN*, 51(11): 907-15.
7. Heinzlbecker J, Gropp T, Weiss C, Huettl K, Stroebel P, Haecker A, Bolenz C, Trojan L (2012) The role of lymph vessel density and lymphangiogenesis in metastatic tumor spread of nonseminomatous testicular germ cell tumors. *UROL ONCOL-SEMIN ORI*, 11: 1078-1439.
8. Herrmann MKA, Kertesz T, Gsänger T, Bloch E, Pollul G, Bouabdallaoui M, Strauss A, Herrmann M, Christiansen H, Wolff HA, Hess CF, Hille A (2012) Gold marker displacement due to needle insertion during HDR-brachytherapy for treatment of prostate cancer: a prospective cone beam computed tomography and kilovoltage on-board imaging (kV-OBI) study. *RADIAT ONCOL*, 7: 24.
9. Loertzer H, Schneider P, Thelen P, Ringert RH, Strauß A (2012) [Laser now also to be used in organ-preserving kidney surgery?]. *UROLOGE*, 51(6): 837-42.
10. Loertzer H, Schneider P, Thelen P, Ringert RH, Strauß A (2012) [Prolapse surgery. With abdominal or vaginal meshes?]. *UROLOGE*, 51(9): 1261-9.
11. Martinschek A, Heinzlmann K, Ritter M, Heinrich E, Trojan L (2012) Radical prostatectomy after previous transurethral resection of the prostate: robot-assisted laparoscopic versus open radical prostatectomy in a matched-pair analysis. *J ENDOUROLOG*, 26(9): 1136-41.
12. May M, Bastian PJ, Brookman-May S, Fritsche HM, Bolenz C, Gilfrich C, Otto W, Trojan L, Herrmann E, Müller SC, Ellinger J, Buchner A, Stief CG, Tilki D, Wieland WF, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Nuhn P, Burger M (2012) External validation of a risk model to predict recurrence-free survival after radical cystectomy in patients with pathological tumor stage T3N0 urothelial carcinoma of the bladder. *J UROLOGY*, 187(4): 1210-4.
13. Nuhn P, May M, Fritsche HM, Buchner A, Brookman-May S, Bolenz C, Moritz R, Herrmann E, Burger M, Höfner T, Ellinger J, Tilki D, Roigas J, Zacharias M, Trojan L, Wülfing C, May F, Melchior S, Haferkamp A, Gilfrich C, Hohenfellner M, Wieland WF, Müller SC, Stief CG, Bastian PJ (2012) External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladder. *EJSO-EUR J SURG ONC*, 38(7): 637-42.
14. Nuhn P, May M, Sun M, Fritsche HM, Brookman-May S, Buchner A, Bolenz C, Moritz R, Herrmann E, Burger M, Tilki D, Trojan L, Perrotte P, Haferkamp A, Hohenfellner M, Wieland WF, Müller SC, Karakiewicz PI, Bastian PJ (2012) External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder. *EUR UROL*, 61(1): 58-64.
15. Ohlmann CH, Merseburger AS, Suttman H, Schilling D, Trojan L, Kempkensteffen C, Corvin S, Mathers MJ, Bastian PJ (2012) Novel options for the treatment of castration-resistant prostate cancer. *WORLD J UROL*, 30(4): 495-503.
16. Otto W, May M, Fritsche HM, Dragun D, Aziz A, Gierth M, Trojan L, Herrmann E, Moritz R, Ellinger J, Tilki D, Buchner A, Höfner T, Brookman-May S, Nuhn P, Gilfrich C, Roigas J, Zacharias M, Denzinger S, Hohenfellner M, Haferkamp A, Müller SC, Kocot A, Riedmiller H, Wieland WF, Stief CG, Bastian PJ, Burger M (2012) Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2500 patients with urothelial carcinoma of the bladder. *GENDER MED*, 9(6): 481-9.
17. Prado LG, Huber J, Huber CG, Mogler C, Ehrenheim J, Nyarangi-Dix J, Pahernik S, Hohenfellner M (2012) Penile methadone injection in suicidal intent: life-threatening and fatal for erectile function. *J ANDROL*, 33(5): 801-4.
18. Schaefer IM, Seeliger S, Strauss A, Füzesi L, Ringert RH, Loertzer H (2012) A three-step technique for umbilicoplasty in a patent urachus. *BJU INT*, 109(4): 640-4.

Urologie

19. Schmitz-Dräger BJ, Lümme G, Bismarck E, Fischer C, Mitglieder des Arbeitskreises Prävention Umwelt und Komplementärmedizin (PUK) der Deutschen Gesellschaft für Urologie e. V. (DGU) (2012) [Prevention of uro-oncological diseases]. UROLOGE, 51(5): 727-36.
20. Stettner M, Krämer G, Strauss A, Kvitkina T, Ohle S, Kieseier BC, Thelen P (2012) Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer. EUR J CANCER PREV, 21(1): 55-64.
21. Thelen P, Ringert RH, Loertzer H, Strauß A (2012) [Intermittent androgen deprivation as therapy for androgen-sensitive prostate cancer. Sense or nonsense?]. UROLOGE, 51(9): 1240-5.
22. Tunn UW, Stenzl A, Schultze-Seemann W, Strauss A, Kindler M, Miller K, Wirth MP, Zantl N, Schulze M, May C, Ruebel A, Birkholz K, Gruenwald V (2012) Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases. CAN J UROL, 19(3): 6261-7.
23. Venkataramani V, Thiele K, Behnes CL, Wulf GG, Thelen P, Opitz L, Salinas-Riester G, Wirths O, Bayer TA, Schweyer S (2012) Amyloid precursor protein is a biomarker for transformed human pluripotent stem cells. AM J PATHOL, 180(4): 1636-52.

Medizinische Dissertationen

1. Fechner A, Dr. med. (2012) Einsatz von alloplastischem Material bei der Korrektur der weiblichen Beckenbodendefekte - Auswertung der Daten der urologischen Klinik der Martin-Luther-Universität Halle-Wittenberg in Anlehnung an aktuelle Literaturdaten. Dissertation Universität Göttingen.
2. Fruchtenicht T, Dr. med. (2012) Die Wirkung von Valproat auf die Knochenmetastasenzellen (VCaP) des Prostatakarzinoms. Dissertation Universität Göttingen.
3. Heider R, Dr. med. (2012) Die Zytokine IL-6 und IL-8 und deren Wert in der Analyse einer Infektion von Lymphozelen. Dissertation Universität Göttingen.
4. Przybyla A, Dr. med. (2012) Vergleich von monopolarer und bipolarer Präparationstechnik bei der radikalen retropubischen Prostatektomie hinsichtlich Komplikationsrate und perioperativer Morbidität. Dissertation Universität Göttingen.
5. Rogalli G, Dr. med. (2012) Retrospektive Analyse der Diagnostik und der Ergebnisse nach Prostatektomie bei 142 an einem Prostatakarzinom erkrankten Patienten. Dissertation Universität Göttingen.
6. Schirdewan C, Dr. med. (2012) Fournier Gangrän: Krankheitsverlauf in Abhängigkeit von Komorbiditäten und Therapie. Dissertation Universität Göttingen.
7. Vowinkel C, Dr. med. (2012) Intraoperative Strahlenbelastung bei Patienten bei der ureterorenoskopischen Steinentfernung. Dissertation Universität Göttingen.